Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Brain Cancer treatment details. Chemotherapy. Radiation. Johns Hopkins, Baltimore, Maryland, United States

Survival: 12.3 months
Toxicity Grade: 5
Treatments: Chemotherapy
Country: United States
City/State/Province: Baltimore, Maryland
Hospital: Johns Hopkins
Journal: Link
Date: 7/2002

Patients: This Phase II study involved 50 newly diagnosed glioblastoma multiforme patients.

Treatment: Treatment consisted of RSR13 (efaproxiral) and standard cranial radiotherapy. RSR13 is a synthetic allosteric modifier of hemoglobin, a radiation-enhancing agent.

Toxicity: One patient died of adult respiratory distress syndrome. A causative or contributory role of RSR13 in this fatal reaction could not be excluded. Twenty-four percent of patients experienced grade 3 or greater RSR13-related toxicity which included: nausea (grade 3), headache (grade 3), allergic rash (grade 3), hypotension (grade 3), transient creatinine increase (grades 2 and 4), and sepsis (grades 3 and 4).

Results: Survival was assessed from the date of histologic diagnosis. Median survival was 12.3 months.

Support: This study was supported in part by Allos Therapeutics. This company markets RSR13 (a.k.a. Efaproxyn (Efaproxiral)).

Correspondence: Lawrence Kleinberg, MD

E-mail to a Friend Email Physician More Information